BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 26447494)

  • 1. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different population-averaged arterial-input-functions in dynamic contrast-enhanced MRI of the prostate: Effects on pharmacokinetic parameters and their diagnostic performance.
    Othman AE; Falkner F; Kessler DE; Martirosian P; Weiss J; Kruck S; Kaufmann S; Grimm R; Kramer U; Nikolaou K; Notohamiprodjo M
    Magn Reson Imaging; 2016 May; 34(4):496-501. PubMed ID: 26708031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of CAIPIRINHA-Dixon-TWIST-VIBE for dynamic contrast-enhanced MRI of the prostate.
    Othman AE; Martirosian P; Schraml C; Taron J; Weiss J; Bier G; Schwentner C; Nickel D; Bamberg F; Kramer U; Nikolaou K; Notohamiprodjo M
    Eur J Radiol; 2015 Nov; 84(11):2110-6. PubMed ID: 26321493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.
    Jena A; Mehta SB; Taneja S
    J Magn Reson Imaging; 2013 Sep; 38(3):573-9. PubMed ID: 23349046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
    Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
    Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.
    Chen J; Qian T; Zhang H; Wei C; Meng F; Yin H
    Magn Reson Imaging; 2016 Feb; 34(2):177-82. PubMed ID: 26518059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
    Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
    J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate.
    Baur AD; Maxeiner A; Franiel T; Kilic E; Huppertz A; Schwenke C; Hamm B; Durmus T
    Invest Radiol; 2014 Jun; 49(6):411-20. PubMed ID: 24598440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
    Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
    J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved detection of hypervascular liver lesions with CAIPIRINHA-Dixon-TWIST-volume-interpolated breath-hold examination.
    Kazmierczak PM; Theisen D; Thierfelder KM; Sommer WH; Reiser MF; Notohamiprodjo M; Nikolaou K
    Invest Radiol; 2015 Mar; 50(3):153-60. PubMed ID: 25478742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of whole-lesion histogram analysis of pharmacokinetic parameters in dynamic contrast-enhanced MRI of breast lesions with the CAIPIRINHA-Dixon-TWIST-VIBE technique.
    Li Z; Ai T; Hu Y; Yan X; Nickel MD; Xu X; Xia L
    J Magn Reson Imaging; 2018 Jan; 47(1):91-96. PubMed ID: 28577335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.
    Ginsburg SB; Taimen P; Merisaari H; Vainio P; Boström PJ; Aronen HJ; Jambor I; Madabhushi A
    J Magn Reson Imaging; 2016 Dec; 44(6):1405-1414. PubMed ID: 27285161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
    Cristel G; Esposito A; Damascelli A; Briganti A; Ambrosi A; Brembilla G; Brunetti L; Antunes S; Freschi M; Montorsi F; Del Maschio A; De Cobelli F
    Eur J Radiol; 2019 Sep; 118():51-57. PubMed ID: 31439258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent.
    Lüdemann L; Nafz B; Elsner F; Grosse-Siestrup C; Meissler M; Kaufels N; Rehbein H; Persson PB; Michaely HJ; Lengsfeld P; Voth M; Gutberlet M
    Invest Radiol; 2009 Mar; 44(3):125-34. PubMed ID: 19151609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging.
    Li Z; Sun J; Chen L; Huang N; Hu P; Hu X; Han G; Zhou Y; Bai W; Niu T; Yang X
    J Magn Reson Imaging; 2016 Jul; 44(1):98-104. PubMed ID: 26707910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
    PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of Benign from Malignant Adnexal Masses by Dynamic Contrast-Enhanced MRI (DCE-MRI): Quantitative and Semi-quantitative analysis at 3-Tesla MRI.
    Gity M; Parviz S; Saligheh Rad H; Fathi Kazerooni A; Shirali E; Shakiba M; Baikpour M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1073-1079. PubMed ID: 31030476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.